☆ 4.6 Article

Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

BLOOD ADVANCES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Herve Tilly et al.

Summary: In untreated intermediate-risk or high-risk DLBCL patients, those who received pola-R-CHP had a lower risk of disease progression, relapse, or death compared to those who received R-CHOP. Overall survival and safety profiles were similar between the two groups.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Hematology

Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients

Sara Harrysson et al.

Summary: A study in Sweden analyzed clinical data of 736 patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and found that most patients experience early relapse and are unable to receive intensive treatment, resulting in poor survival. Even patients eligible for CAR T trials had unfavorable outcomes, serving as a benchmark for evaluating the efficacy of novel therapies.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study

Ron Ram et al.

Summary: The efficacy and safety of CAR-T cell therapy were comparable between elderly and younger patients, suggesting that age should not be a barrier for CAR-T cell administration. However, elderly patients may require longer rehabilitation therapy to improve disabilities and long-term symptoms.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Hematology

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP

Toby A. Eyre et al.

Summary: Elderly DLBCL patients have increased risk of infection-related hospitalization and death during and after R-CHOP treatment, with IDI >80% and primary quinolone prophylaxis independently associated with reduced risk. Key factors associated with infection-related death include IPI score, CIRS-G score, and low albumin levels, allowing for the development of a predictive risk score. Targeted antimicrobial prophylaxis for high-risk patients may require further randomized trials.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Sattva S. Neelapu et al.

BLOOD (2020)

添加到收藏夹

Review Hematology

Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis

Marijke Linschoten et al.

LANCET HAEMATOLOGY (2020)

添加到收藏夹

Article Oncology

Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Yucai Wang et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer

Enrique Soto-Perez-de-Celis et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

Gustaaf W. van Imhoff et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Hematology

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump et al.

BLOOD (2017)

添加到收藏夹

Article Oncology

Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial

A. Kuhnl et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes

Lauren R. Teras et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2016)

添加到收藏夹

Article Education, Scientific Disciplines

Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

Bertrand Coiffier et al.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)

添加到收藏夹

Article Oncology

Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma

Alexandra Smith et al.

CANCER EPIDEMIOLOGY (2015)

添加到收藏夹

Article Hematology

Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation

Mehdi Hamadani et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)

添加到收藏夹

Review Oncology

Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic

Tanya M. Wildes et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)

添加到收藏夹

Article Oncology

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

Richard Delarue et al.

LANCET ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Christian Gisselbrecht et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Oncology

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

Thomas M. Habermann et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

添加到收藏夹

Article Medicine, General & Internal

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

B Coiffier et al.

NEW ENGLAND JOURNAL OF MEDICINE (2002)

添加到收藏夹

Article Oncology

Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

JM Vose et al.

JOURNAL OF CLINICAL ONCOLOGY (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.